Value through InnovationDecember 19 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim press releases. To quickly find all press releases on a specific topic, please use the search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10

New Data Show Idarucizumab* Reverses Anticoagulant Effects of Dabigatran (PRADAXA®) in Middle-Aged, Elderly and Renally Impaired Volunteers


Boehringer Ingelheim Receives Perfect Rating on Human Rights Campaign Foundation’s Corporate Equality Index


National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes


Interim Data Reinforce Safety and Effectiveness of Pradaxa® (dabigatran etexilate mesylate) versus Warfarin in Routine Care of Patients with Non-valvular Atrial Fibrillation


New Data Show Idarucizumab* Restores Wound-Site Formation of Fibrin, a Key Component of Blood Clotting, in Healthy Volunteers Given Pradaxa® (dabigatran etexilate mesylate)


New Survey Uncovers Critical Need to Break Down Barriers and Improve Communication and Education about the Link between Atrial Fibrillation and Devastating Impact of Stroke


New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes


U.S. Department of Defense Study Supports Favorable Benefit-Risk Profile of Pradaxa® (dabigatran etexilate mesylate) for Reducing Stroke Risk in Non-valvular Atrial Fibrillation


Boehringer Ingelheim, WellPoint and HealthCore Announce First Project Under Multi-Year Research Collaboration


Boehringer Ingelheim Initiates U.S. Sites in First-Ever Global Phase III Trial of Investigational Antidote in Patients Taking PRADAXA® (dabigatran etexilate mesylate)

back 1 2 3 4 5 6 7 8 9 10